Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model

Frontiers in Pharmacology - Tập 13
Maurício dos Santos Pereira1, Glauce Crivelaro Nascimento1, Mariza Bortolanza1, Patrick P. Michel2, Rita Raisman‐Vozari2, Elaine Del‐Bel1
1Department of Basic and Oral Biology, FORP, Campus USP, University of São Paulo, Ribeirão Preto, Brazil
2Sorbonne Université, Paris Brain Institute-ICM, Inserm, CNRS, APHP, Hôpital de La Pitié Salpêtrière, Paris, France

Tóm tắt

The pharmacological manipulation of neuroinflammation appears to be a promising strategy to alleviate l-DOPA-induced dyskinesia (LID) in Parkinson’s disease (PD). Doxycycline (Doxy), a semisynthetic brain-penetrant tetracycline antibiotic having interesting anti-inflammatory properties, we addressed the possibility that this compound could resolve LID in l-DOPA-treated C57BL/6 mice presenting either moderate or intermediate lesions of the mesostriatal dopaminergic pathway generated by intrastriatal injections of 6-OHDA. Doxy, when given subcutaneously before l-DOPA at doses of 20 mg kg−1 and 40 mg kg−1, led to significant LID reduction in mice with moderate and intermediate dopaminergic lesions, respectively. Importantly, Doxy did not reduce locomotor activity improved by l-DOPA. To address the molecular mechanism of Doxy, we sacrificed mice with mild lesions 1) to perform the immunodetection of tyrosine hydroxylase (TH) and Fos-B and 2) to evaluate a panel of inflammation markers in the striatum, such as cyclooxygenase-2 and its downstream product Prostaglandin E2 along with the cytokines TNF-α, IL-1β and IL-6. TH-immunodetection revealed that vehicle and Doxy-treated mice had similar striatal lesions, excluding that LID improvement by Doxy could result from neurorestorative effects. Importantly, LID inhibition by Doxy was associated with decreased Fos-B and COX-2 expression and reduced levels of PGE2, TNF-α, and IL-1β in the dorsolateral striatum of dyskinetic mice. We conclude 1) that Doxy has the potential to prevent LID regardless of the intensity of dopaminergic lesioning and 2) that the anti-inflammatory effects of Doxy probably account for LID attenuation. Overall, the present results further indicate that Doxy might represent an attractive and alternative treatment for LID in PD.

Từ khóa


Tài liệu tham khảo

Amaral, 2021, The antibiotic doxycycline mimics the ngf signaling in PC12 cells: A relevant mechanism for neuroprotection, Chem. Biol. Interact., 341, 109454, 10.1016/j.cbi.2021.109454

Andersson, 1976, The penetration of doxycycline into CSF, Scand. J. Infect. Dis. Suppl., 17

Barnum, 2008, Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: Role for interleukin-1beta, Neuroscience, 156, 30, 10.1016/j.neuroscience.2008.07.016

Beck, 2019, Role of striatal ΔFosB in l-Dopa-induced dyskinesias of parkinsonian nonhuman primates, Proc. Natl. Acad. Sci. U. S. A., 116, 18664, 10.1073/pnas.1907810116

Binh, 2009, Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects, Am. J. Trop. Med. Hyg., 81, 747, 10.4269/ajtmh.2009.09-0214

Bortolanza, , Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease, Neurobiol. Dis., 73, 377, 10.1016/j.nbd.2014.10.017

Bortolanza, , Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?, Philos. Trans. R. Soc. Lond. B Biol. Sci., 370, 20140190, 10.1098/rstb.2014.0190

Bortolanza, 2016, Antidyskinetic effect of 7-nitroindazole and sodium nitroprusside associated with amantadine in a rat model of Parkinson's disease, Neurotox. Res., 30, 88, 10.1007/s12640-016-9618-4

Bortolanza, 2018, Tetracycline repurposing in neurodegeneration: Focus on Parkinson's disease, J. Neural Transm., 125, 1403, 10.1007/s00702-018-1913-1

Bortolanza, 2021, Doxycycline and its derivative, COL-3, decrease dyskinesia induced by L-DOPA in hemiparkinsonian rats, Br. J. Pharmacol., 178, 2595, 10.1111/bph.15439

Carta, 2017, l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?, Eur. J. Neurosci., 45, 73, 10.1111/ejn.13482

Castro, 2009, Pharmacokinetics of doxycycline in sheep after intravenous and oral administration, Vet. J., 180, 389, 10.1016/j.tvjl.2008.02.001

Cenci, 2006, Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia, J. Neurochem., 99, 381, 10.1111/j.1471-4159.2006.04124.x

Cenci, 1998, L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA, Eur. J. Neurosci., 10, 2694, 10.1046/j.1460-9568.1998.00285.x

Cenci, 2020, Dyskinesia matters, Mov. Disord., 35, 392, 10.1002/mds.27959

Cenci, 2014, Presynaptic mechanisms of l-DOPA-induced dyskinesia: The findings, the debate, and the therapeutic implications, Front. Neurol., 5, 242, 10.3389/fneur.2014.00242

Cerri, 2019, Parkinson's disease in women and men: What's the difference?, J. Park. Dis., 9, 501, 10.3233/JPD-191683

Cho, 2009, Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3, Neurotox. Res., 16, 361, 10.1007/s12640-009-9078-1

Chopra, 2001, Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance, Microbiol. Mol. Biol. Rev., 65, 232, 10.1128/MMBR.65.2.232-260.2001

Del-Bel, 2016, l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?, Synapse, 70, 479, 10.1002/syn.21941

Dominguez-Meijide, 2021, Doxycycline inhibits alpha-synuclein-associated pathologies in vitro and in vivo, Neurobiol. Dis., 151, 105256, 10.1016/j.nbd.2021.105256

Dos Santos Pereira, 2020, Contributive role of TNF-alpha to L-DOPA-induced dyskinesia in a unilateral 6-OHDA lesion model of Parkinson's disease, Front. Pharmacol., 11, 617085, 10.3389/fphar.2020.617085

Dos-Santos-Pereira, 2016, Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action, Neurobiol. Dis., 94, 179, 10.1016/j.nbd.2016.06.013

Egeberg, 2016, Exploring the association between Rosacea and Parkinson disease: A Danish nationwide cohort study, JAMA Neurol., 73, 529, 10.1001/jamaneurol.2016.0022

Ferreira Junior, 2021, The Chemically-Modified Tetracycline COL-3 and Its Parent Compound Doxycycline Prevent Microglial Inflammatory Responses by Reducing Glucose-Mediated Oxidative Stress, Cells, 10

Feyder, 2011, L-DOPA-Induced dyskinesia and abnormal signaling in striatal medium spiny neurons: Focus on dopamine D1 receptor-mediated transmission, Front. Behav. Neurosci., 5, 71, 10.3389/fnbeh.2011.00071

Giarratano, 2018, Review of antimicrobial use and considerations in the elderly population, Clin. Interv. Aging, 13, 657, 10.2147/CIA.S133640

Grealish, 2010, Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease, Eur. J. Neurosci., 31, 2266, 10.1111/j.1460-9568.2010.07265.x

Griffin, 2011, Tetracycline compounds with non-antimicrobial organ protective properties: Possible mechanisms of action, Pharmacol. Res., 63, 102, 10.1016/j.phrs.2010.10.004

Gu, 2012, Non-antibacterial tetracycline formulations: Clinical applications in dentistry and medicine, J. Oral Microbiol., 4, 19227, 10.3402/jom.v4i0.19227

Huot, 2013, The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease, Pharmacol. Rev., 65, 171, 10.1124/pr.111.005678

Iancu, 2005, Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice, Behav. Brain Res., 162, 1, 10.1016/j.bbr.2005.02.023

Johansson, 2015, Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models, J. Clin. Invest., 125, 350, 10.1172/JCI77487

Junior, 2020, Cannabidiol and cannabinoid compounds as potential strategies for treating Parkinson's disease and L-DOPA-induced dyskinesia, Neurotox. Res., 37, 12, 10.1007/s12640-019-00109-8

Konradi, 2004, Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia, Neurobiol. Dis., 17, 219, 10.1016/j.nbd.2004.07.005

Kordower, 2013, Disease duration and the integrity of the nigrostriatal system in Parkinson's disease, Brain, 136, 2419, 10.1093/brain/awt192

Lazzarini, 2013, Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model, Glia, 61, 1084, 10.1002/glia.22496

Lucchetti, 2019, Plasma and brain concentrations of doxycycline after single and repeated doses in wild-type and APP23 mice, J. Pharmacol. Exp. Ther., 368, 32, 10.1124/jpet.118.252064

Montagna, 2013, Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis, Amyloid, 20, 173, 10.3109/13506129.2013.803463

Morissette, 2022, Prevention of L-dopa-induced dyskinesias by MPEP blockade of metabotropic glutamate receptor 5 is associated with reduced inflammation in the brain of parkinsonian monkeys, Cells, 11, 691, 10.3390/cells11040691

Mortison, 2018, Tetracyclines modify translation by targeting key human rRNA substructures, Cell Chem. Biol., 25, 1506, 10.1016/j.chembiol.2018.09.010

Mulas, 2016, Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease, Exp. Neurol., 286, 83, 10.1016/j.expneurol.2016.09.013

Nakao, 2002, Tumor necrosis factor alpha (TNF-alpha)-induced prostaglandin E2 release is mediated by the activation of cyclooxygenase-2 (COX-2) transcription via NFkappaB in human gingival fibroblasts, Mol. Cell. Biochem., 238, 11, 10.1023/a:1019927616000

Neeb, 2011, IL-1β stimulates COX-2 dependent PGE₂ synthesis and CGRP release in rat trigeminal ganglia cells, Plos One, 6, e17360, 10.1371/journal.pone.0017360

Olanow, 2020, Continuous dopaminergic stimulation as a treatment for Parkinson's disease: Current status and future opportunities, Mov. Disord., 35, 1731, 10.1002/mds.28215

Orsucci, 2009, Neuroprotective effects of tetracyclines: Molecular targets, animal models and human disease, CNS Neurol. Disord. Drug Targets, 8, 222, 10.2174/187152709788680689

Padovan-Neto, 2015, Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats, Neuropharmacology, 89, 87, 10.1016/j.neuropharm.2014.08.019

Park, 2020, Immunotherapy of autoimmune diseases with nonantibiotic properties of tetracyclines, Immune Netw., 20, e47, 10.4110/in.2020.20.e47

Pavon, 2006, ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice, Biol. Psychiatry, 59, 64, 10.1016/j.biopsych.2005.05.044

Pisanu, 2018, Neuroinflammation in L-DOPA-induced dyskinesia: Beyond the immune function, J. Neural Transm., 125, 1287, 10.1007/s00702-018-1874-4

Saivin, 1988, Clinical pharmacokinetics of doxycycline and minocycline, Clin. Pharmacokinet., 15, 355, 10.2165/00003088-198815060-00001

Santa-Cecilia, 2016, Doxycycline Suppresses Microglial Activation by Inhibiting the p38 MAPK and NF-kB Signaling Pathways, Neurotox, 29, 447, 10.1007/s12640-015-9592-2

Santa-Cecilia, 2019, The neuroprotective effect of doxycycline on neurodegenerative diseases, Neurotox. Res., 35, 981, 10.1007/s12640-019-00015-z

Santos-Lobato, 2022, Doxycycline to treat levodopa-induced dyskinesias in Parkinson’s disease: A proof-of-concept study, 10.1101/2022.05.13.22275023

Sebastianutto, 2018, mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia, Curr. Opin. Pharmacol., 38, 81, 10.1016/j.coph.2018.03.003

Vargas-Estrada, 2008, Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats, Arzneimittelforschung., 58, 310, 10.1055/s-0031-1296512

Walker, 2005, Long-term treatment with sub-antimicrobial dose doxycycline has no antibacterial effect on intestinal flora, J. Clin. Periodontol., 32, 1163, 10.1111/j.1600-051X.2005.00840.x

Wang, 2017, Low dose doxycycline decreases systemic inflammation and improves glycemic control, lipid profiles, and islet morphology and function in db/db mice, Sci. Rep., 7, 14707, 10.1038/s41598-017-14408-7

Thông tin
Thông tin xuất bản

Frontiers in Pharmacology

Tập 13

Thông tin tác giả